Pelthos Therapeutics
Manufacturing · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4020 Stirrup Creek Dr Ste 110, Durham, N...Phone Number
(919) 908-2400Website
www.pelthos.comRevenue
$27.7 MillionStock Symbol
PTHSIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Pelthos Therapeutics
Pelthos Therapeutics (pelthos.com) is a Durham, North Carolinabased commercialstage biopharmaceutical company focused on dermatology and cutaneous infectious diseases, commercializing ZELSUVMI (berdazimer) topical gel for molluscum contagiosum and advancing additional nitricoxidebased therapeutic products using its proprietary NITRICIL drugdelivery platform.Explore more
Pelthos Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pelthos Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Pelthos Therapeutics launches new products
Check out if Pelthos Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Pelthos Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Pelthos Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Pelthos Therapeutics
Check if Pelthos Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Pelthos Therapeutics has new funding data
Pelthos Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Pelthos Therapeutics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Pelthos Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pelthos Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pelthos Therapeutics.
Pelthos Therapeutics financials insights
Gather financial insights about Pelthos Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$50.1M
2026
Debt
$50M
Pelthos Therapeutics Tech Stack
Most Recent Scoops
Earnings
reported net product revenue of $9.1 million for Q4 2025, driven by a 129% increase in prescriptions from 2,716 units in Q3 to 6,232 units in Q4, as reported by Symphony Health. This revenue increased from $7.1 million in Q3 2025.
Earnings, Finance
Earnings
reported 5,297 prescribed units for ZELSUVMI from January 1, 2026 through the week ending March 6, 2026, recently hitting an all-time high of 695 prescribed units in one week.
Pharmaceuticals
Earnings
reported significant prescription growth despite Q4 being historically the weakest annual quarter for molluscum contagiosum claims. The average monthly MC claims in Q4 averaged approximately 33,700 claims per month, compared to approximately 45,100 claims per month for March through October 2025.
Pharmaceuticals
Earnings
reported that on the balance sheet, the $3.8 million in other short-term liabilities and the $30.1 million in other long-term liabilities are largely the result of the fair value assessment of future royalty obligations. These are not general obligations, and the amounts related thereto will be recognized with the payment of actual royalties resulting from actual net sales.
Accounting, Financial Reporting, Finance
Earnings
Logistics / Supply Chain, Inventory Management
Pelthos Therapeutics News & Media
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
DURHAM, N.C., July 24, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS) (the “Company” or “Pelthos”) today announced that it will hold its 2026 Annual Meeting of Stockholders virtually on Tuesday, September 29, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of the close of business on August 4, 2026 are entitled to notice of and to vote at the 2026 Annual Meeting. The Company anticipates filing the Notice of AnnualPelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
DURHAM, N.C., June 30, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective when the US market opened on June 29 as part of the 2026 Russell indexes reconstitution.Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies repPelthos Therapeutics Announces First Quarter 2026 Financial Results
ZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Pelthos Therapeutics
Sign Up For FreeTo access detailed company insights
Pelthos Therapeutics (pelthos.com) is a Durham, North Carolinabased commercialstage biopharmaceutical company focused on dermatology and cutaneous infectious diseases, commercializing ZELSUVMI (berdazimer) topical gel for molluscum contagiosum and advancing additional nitricoxidebased therapeutic products using its proprietary NITRICIL drugdelivery... Read More
